Connect with us

Business

Top stocks to buy today: Stock recommendations for December 5, 2025 – check list – The Times of India

Published

on

Top stocks to buy today: Stock recommendations for December 5, 2025 – check list – The Times of India


Top stocks to buy (AI image)

Stock market recommendations: According to Bajaj Broking Research, the top stock picks for December 5, 2025 are Max Healthcare, and Tata Power. Here’s its view on Nifty and Bank Nifty:Index View: NIFTYBenchmark indices spent the previous week oscillating within a defined consolidation band, digesting their recent up move. The Nifty registered a fresh lifetime peak of 26,325 during Monday’s trade. However, lost momentum at elevated levels amid bouts of profit-taking, triggered in part by renewed pressure on the Indian rupee, which depreciated to a record low against the US dollar. Persistent foreign portfolio outflows (FPI selling) further exacerbated currency weakness, injecting a note of caution into risk sentiment.In the near term, market trajectory is likely to be dictated by currency stabilization dynamics, especially whether the rupee can find a durable floor. Additionally, investors will be closely tracking the RBI’s upcoming monetary policy statement for cues on the central bank’s stance regarding inflation management, liquidity calibration, and potential interventions to support the rupee. On the global front, the US FOMC policy outcome will remain a critical macro catalyst, shaping expectations around global rate differentials and capital flows. Moreover, clarity on evolving India–US trade negotiations could influence sector-specific outlooks, particularly in export-linked and tariff-sensitive industries. A key observation on the Nifty daily chart is that the entire up-move over the past two months has remained well within a rising channel, indicating sustained buying interest at higher levels and reinforcing an overall positive bias.We believe the current 3-4 sessions breather should be used to accumulate quality stocks in a staggered manner for the next leg of up move towards 26,500 and then towards 26,800 in the coming weeks being the measuring implication of the recent range breakout and the upper band of the last two months rising channel.Nifty has key support in the range of 25700-25900 being the confluence of the 50-day EMA, the bullish gap from November 12 and the lower band of the rising channel of the last two months. Holding above the support area will keep the overall bias positive and only a breakdown below the support area will signal a pause in the current positive trend. NIFTY BANKBank Nifty traded in a range, digesting its last four weeks strong gains. Earlier during the week, it formed a fresh all-time high of 26114. However, profit booking at higher levels saw the index traded in a range ahead of the RBI monetary policy outcome.We expect the index to consolidate and form a base in the range of 58500-60100 in the coming sessions. A follow through strength above Monday’s high (60114) will open further upside towards 60,400 and then towards 61,000 levels in the coming weeks.The entire up move of the last 2 months is well channelled signaling sustained demand at elevated levels. Key support is placed at 58,300-58,600 levels being the confluence of the last two weeks lows and recent breakout area. Holding above the support area will keep the short-term bias positive.

Stock Recommendations:

Max HealthcareBuy in the range of ₹ 1070-1090

Target Return Time Period
₹ 1190 10% 6 Months

The stock is forming base at the 52 week EMA and the 61.8% retracement of the previous major up move (940-1314).We believe the current decline is approaching price and time wise maturity and the stock is likely to resume up move and head towards 1190 levels being the confluence of the high of November and key retracement area. The daily stochastic has approached extreme oversold territory and we expect the stock to resume its positive momentum in the coming weeks.Tata PowerBuy in the range of 381-386

Target Return Time Period
₹ 430 12% 6 Months

Tata Power continues to trade sideways on the daily timeframe, oscillating within a well-defined range of ₹380–₹420. The stock is currently forming a rectangle pattern, with consistent buying support emerging near the ₹380 zone.Historically, the counter has shown a tendency to rebound from these lower levels and head towards the upper end of the range, which lies near ₹420.Given the prevailing price structure and renewed momentum, the stock appears poised to extend its upward trajectory, first towards the upper band of ₹420, and potentially up to ₹430, which aligns with the 127.2% Fibonacci extension of the previous swing.(Disclaimer: Recommendations and views on the stock market, other asset classes or personal finance management tips given by experts are their own. These opinions do not represent the views of The Times of India)





Source link

Business

How Costly Is A $10 Oil Spike For India’s Economy?

Published

on

How Costly Is A  Oil Spike For India’s Economy?


Last Updated:

Every $10 rise in global crude oil prices could shave around 0.5 percentage points off India’s GDP growth, say experts

India imports nearly 50 percent of crude oil from the Middle East

India imports nearly 50 percent of crude oil from the Middle East

Every $10 rise in global crude oil prices could shave around 0.5 percentage points off India’s GDP growth, underscoring the country’s heavy reliance on imported oil and vulnerability to global energy volatility, Vandana Bharti, Research Head–Commodity at SMC Global Securities, told ANI.

In an interview with ANI, Bharti said escalating geopolitical tensions in West Asia pose a significant economic risk for India as crude prices climb and supply chains face potential disruptions.

“Every $10 increase in crude oil prices impacts India’s GDP by roughly 0.5%. We have already seen prices rise by about $10–$15 recently, and the economic impact will eventually reflect in growth numbers,” she said.

West Asia tensions driving oil prices higher

The surge in oil prices follows intensifying tensions involving the United States, Israel and Iran, particularly around the Strait of Hormuz — a critical maritime corridor through which roughly 20–25% of global oil shipments pass.

Bharti said the conflict has injected additional uncertainty into global energy markets and added what she described as a “war premium” to crude prices.

“It’s not just about the possibility of the Strait of Hormuz closing. Insurance costs and freight charges are rising, and shipments are being rerouted. All these factors add a war premium to crude oil prices and increase market uncertainty,” she said.

Risks extend beyond shipping

According to Bharti, the risks go beyond maritime routes and extend to energy infrastructure itself.

“Energy sites such as crude oil facilities and LNG plants are potential targets. There are also concerns about seabed cables and other critical infrastructure. So the threat is not only to energy supply but also to broader global trade and connectivity,” she noted.

Crude prices rise sharply

Oil prices have already surged as tensions intensified in the region.

Bharti said crude climbed from around $69 per barrel to nearly $78 per barrel within a week.

“In just one week we have seen prices move from about $69 to $78 per barrel. If tensions persist, crude could rise further to around $85–$87 per barrel in the coming days,” she said.

India’s reliance on Middle Eastern crude

India remains particularly vulnerable to such price shocks due to its heavy dependence on imported oil.

Bharti noted that roughly half of India’s crude imports come from the Middle East, and many domestic refineries are specifically configured to process Middle Eastern crude grades.

“India imports nearly 50% of its crude from the Middle East, so any disruption in the region directly impacts supply availability and pricing,” she said.

India maintains strategic petroleum reserves that can help cushion short-term disruptions, but Bharti emphasised that these are primarily meant for emergencies.

“We have reserves that can last about 25–30 days in emergency situations, but the structural dependence on Middle Eastern supply remains,” she said.

She added that even brief supply disruptions could trigger volatility across Asian financial markets.

“Even a two-week disruption could create significant volatility in Asia. We are already seeing pressure on currencies, equity outflows and rising economic uncertainty,” Bharti said.

Diversification may cushion the impact

Bharti said India could mitigate some risks by diversifying crude supply sources.

“Russia has been offering crude at discounted prices, so India may increase purchases from Russia or other suppliers if required. Adjusting supply chains and renegotiating trade arrangements can provide some relief,” she said.

She also pointed out that members of the Organization of the Petroleum Exporting Countries (OPEC) may attempt to stabilise prices, although security concerns could limit immediate production increases.

Impact on fertilisers and agriculture

Higher crude prices could also ripple into other sectors of the economy.

Bharti warned that rising energy costs may push up fertiliser prices and agricultural input costs, potentially affecting the upcoming kharif crop season.

“Higher energy costs could make fertilisers and farm inputs more expensive, which may increase the cost of cultivation for farmers,” she said.

Renewables gain strategic importance

Bharti added that the ongoing geopolitical tensions highlight the need for countries to accelerate the transition to renewable energy.

“Events like this are a wake-up call. Governments may increasingly prioritise renewable energy such as solar to reduce dependence on volatile fossil-fuel supply routes,” she said.

Click here to add News18 as your preferred news source on Google.

Check Iran Israel War News Today Live Updates.

Follow News18 on Google. Join the fun, play games on News18. Stay updated with all the latest business news, including market trends, stock updates, tax, IPO, banking finance, real estate, savings and investments. To Get in-depth analysis, expert opinions, and real-time updates. Also Download the News18 App to stay updated.

Disclaimer: Comments reflect users’ views, not News18’s. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.

Read More



Source link

Continue Reading

Business

Anthropic officially designated a supply chain risk by Pentagon

Published

on

Anthropic officially designated a supply chain risk by Pentagon



The supply chain risk designation of the artificial intelligence firm is a first for a US company.



Source link

Continue Reading

Business

FDA official calls UniQure’s gene therapy a ‘failed’ treatment for Huntington’s disease

Published

on

FDA official calls UniQure’s gene therapy a ‘failed’ treatment for Huntington’s disease


Thomas Fuller | SOPA Images | Lightrocket | Getty Images

UniQure needs to run another study to prove that its gene therapy “actually helps people with Huntington’s disease,” a senior U.S. Food and Drug Administration official said on a call with reporters Thursday.

The official, who requested anonymity before discussing sensitive information, confirmed the agency has asked the company to run a placebo controlled trial of its treatment, which is administered directly into the brain. UniQure has said that type of study isn’t ethical because it would require putting people under general anesthesia for hours, a characterization the official disputed.

“So what is really going on? UniQure is the latest company to make a failed therapy for Huntington’s patients,” the official said. “They likely acknowledge or understand at some deep level that their trial failed years ago, and instead of doing the right thing and running the correct clinical study, UniQure is performing a distorted or manipulated comparison in the mind of FDA.”

The comments mark the latest development in a messy public spat between UniQure and the FDA, and as the agency comes under fire for a number of recent drug approval application rejections, including some where companies have accused it of going back on previous guidance. FDA Commissioner Marty Makary in an interview with CNBC’s Becky Quick last week seemingly criticized UniQure’s gene therapy for Huntington’s disease. Makary didn’t name UniQure but described its treatment.

UniQure then accused the FDA of reversing its stance that the company’s clinical trial data would be sufficient to seek approval. UniQure’s study used an outside database to measure how patients with Huntington’s disease might decline without treatment, known as an external control. UniQure has said it wouldn’t be feasible to run a true randomized, double-blind placebo-controlled study, considered the gold standard, because it wouldn’t be ethical to make people undergo a sham hours-long brain surgery.

The FDA official said the agency “never agreed to accept this distorted comparison” and the FDA “never makes such assurances.” Instead, the “FDA will always say, ‘Well, we have to see the data when we get it.'”

UniQure didn’t immediately comment.

The company’s stock rose more than 10% on Thursday and has fallen 58% this year as of Thursday afternoon.



Source link

Continue Reading

Trending